trending Market Intelligence /marketintelligence/en/news-insights/trending/8thtp4cojpdp6z8m1wot3a2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

MabVax Therapeutics exploring sale of clinical, preclinical assets

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


MabVax Therapeutics exploring sale of clinical, preclinical assets

MabVax Therapeutics Holdings Inc. said it is exploring a sale of its clinical and preclinical assets.

The assets hold "substantial value" but "the cost of execution for continuing development in the near term exceeds our current financial resources," said David Hansen, MabVax president and CEO.

The San Diego-based cancer and pancreatitis drug developer engaged Objective Capital Partners as financial adviser, to help assess options for a potential sale. MabVax intends to complete the sale process by January 2019.

In July, MabVax sold its antibody development program targeting multiple solid tumor cancers to Boehringer Ingelheim GmbH. The same month, the company said it will not appeal a delisting decision by Nasdaq, resulting in the suspension of its common stock from the Nasdaq Capital Market.